[{"address1": "201 Elliott Avenue West", "address2": "Suite 260", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 568 1466", "website": "https://impelpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.", "fullTimeEmployees": 160, "companyOfficers": [{"maxAge": 1, "name": "Mr. Leonard S. Paolillo", "age": 44, "title": "Interim President & CEO", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": 523967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John D. Hoekman Ph.D.", "age": 42, "title": "Co-Founder and Chief Technology & Development Officer", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sarah  Wille", "title": "Vice President of Human Resources", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Youmans", "age": 56, "title": "Senior Vice President of Technical Operations", "yearBorn": 1967, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brandon  Smith", "title": "Chief Restructuring Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.05, "open": 0.05, "dayLow": 0.0401, "dayHigh": 0.0503, "regularMarketPreviousClose": 0.05, "regularMarketOpen": 0.05, "regularMarketDayLow": 0.0401, "regularMarketDayHigh": 0.0503, "beta": 0.854, "forwardPE": -0.046091955, "volume": 8161, "regularMarketVolume": 8161, "averageVolume": 1031968, "averageVolume10days": 54730, "averageDailyVolume10Day": 54730, "marketCap": 958390, "fiftyTwoWeekLow": 0.021, "fiftyTwoWeekHigh": 3.71, "priceToSalesTrailing12Months": 0.04566589, "fiftyDayAverage": 0.26782, "twoHundredDayAverage": 0.875245, "currency": "USD", "enterpriseValue": 115517392, "floatShares": 8687661, "sharesOutstanding": 23900000, "sharesShort": 851499, "sharesShortPriorMonth": 808771, "sharesShortPreviousMonthDate": 1698710400, "dateShortInterest": 1701302400, "sharesPercentSharesOut": 0.0356, "heldPercentInsiders": 0.00113, "heldPercentInstitutions": 0.71489996, "shortRatio": 0.36, "shortPercentOfFloat": 0.1088, "impliedSharesOutstanding": 23900000, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -74279000, "forwardEps": -0.87, "enterpriseToRevenue": 5.504, "enterpriseToEbitda": -1.675, "52WeekChange": -0.98533726, "SandP52WeekChange": 0.20484698, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "IMPLQ", "underlyingSymbol": "IMPLQ", "shortName": "IMPEL PHARMACEUTICALS INC", "longName": "Impel Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1619184600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "72d3d0a6-853b-385c-9c08-c7d9eb9d9f4c", "messageBoardId": "finmb_98729358", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.0401, "targetHighPrice": 40.0, "targetLowPrice": 40.0, "targetMeanPrice": 40.0, "targetMedianPrice": 40.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 239000, "totalCashPerShare": 0.01, "ebitda": -68956000, "totalDebt": 114798000, "quickRatio": 0.055, "currentRatio": 0.188, "totalRevenue": 20987000, "revenuePerShare": 0.884, "returnOnAssets": -0.62491, "freeCashflow": -57814376, "operatingCashflow": -79093000, "revenueGrowth": 0.63, "grossMargins": 0.5258, "operatingMargins": -2.5504699, "financialCurrency": "USD", "trailingPegRatio": null}]